Immunotherapy: Macrophages steal the show. Villanueva MT. Nat Rev Cancer. 2017, June 23; 17(7):396-397.PD-1 expression by tumour associated macrophages inhibits phagocytosis and tumour immunity. Gordon, S. R. etal. 2017, Nature. 545, 495–499.
Invivo imaging reveals a tumor-associated macrophage mediated resistance pathway in anti-PD-1 therapy. Arlauckas, S. P.etal. Sci. Transl Med. 2017, 9, eaal3604.
Cooperation of immune lymphoid cells with macrophages in tumour immunity. Evans, R. & Alexander, P. Nature. 1970, 228,620–622.
Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity. Mantovani, A. 1978, Int. J. Cancer 22, 741–746.
Tumour-associated macrophages as treatment targets in oncology. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Nat Rev Clin Oncol. 2017, Jul;14(7):399-416.
CSF-1/CSF-1R targeting agents in clinical development for cancer therapy. Ries CH, et. al. Curr Opin Pharmacol. 2015, 23:45-51.
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Ries CH, et. al. Cancer Cell. 2014, 25(6):846-859.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Cassier PA et al. Lancet Oncol. 2015, 16(8):949-956.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. William D. Tap, M.D., Zev A. Wainberg, et. al. N Engl J Med. 2015, 373:428-437.
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Kojima Y, et al.2016, Nature 536:86-90.
CD47 blockade as another immune checkpoint therapy for cancer. Vonderheide RH. Nat Med 2015, 21:1122-1123.
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, nonrandomised, phase 1b trial. Nywening, T. M. et al. Lancet Oncol. 2016,17:651–662.
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Beatty, G. L. et al. Clin. Cancer Res. 2013, 19:6286–6295.